<DOC>
	<DOCNO>NCT01256762</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety treatment imetelstat + paclitaxel ( without bevacizumab ) versus paclitaxel ( without bevacizumab ) alone patient locally recurrent metastatic breast cancer receive chemotherapy receive one non-taxane base chemotherapy metastatic breast cancer .</brief_summary>
	<brief_title>Imetelstat Combination With Paclitaxel ( With Without Bevacizumab ) Patients With Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>Patients randomize 1:1 ratio imetelstat + paclitaxel ( without bevacizumab ) versus paclitaxel ( without bevacizumab ) alone .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Inclusion Criteria Histologically cytologically confirm adenocarcinoma breast either locally recurrent metastatic . Locally recurrent disease must amenable surgical resection radiation curative intent Either receive chemotherapy may one prior nontaxane chemotherapy regimen metastatic disease ( restriction prior hormonal therapy ) Prior use bevacizumab allow provide administered combination taxane ECOG performance status 01 Adequate bone marrow reserve indicate : ANC &gt; 1500/uL ( without use growth factor within 7 day ) Platelet count &gt; 100,000 ( without transfusion prior 7 day ) Hemoglobin &gt; 9.0 g/dL Women pregnant breast feed Locally recurrent disease amenable resection curative intent HER2positive breast cancer Active central nervous system ( CNS ) metastatic disease include patient receive radiotherapy and/or steroid treatment ( within last 3 month ) Prior adjuvant neoadjuvant taxane chemotherapy within 12 month prior first relapse Investigational therapy within 4 week first study drug administration Prior radiation , cytotoxic , hormonal therapy within 2 week first study drug administration Therapeutic anticoagulation regular use antiplatelet therapy within 2 week prior first study drug administration ( low dose anticoagulant therapy maintain patency vascular access device allow ) Grade â‰¥ 2 neuropathy Uncontrolled clinically significant atrial ventricular arrhythmia ( unless pacemaker place ) Severe conduction disturbance include clinically significant QTC prolongation &gt; 450 m ( unless pacemaker place ) Active chronically recurrent bleeding ( e.g. , active peptic ulcer disease ) Clinically relevant active infection Known positive serology human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>imetelstat</keyword>
	<keyword>imetelstat sodium</keyword>
	<keyword>GRN163L</keyword>
	<keyword>telomerase inhibitor</keyword>
	<keyword>telomerase inhibition</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>locally recurrent breast cancer</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Avastin</keyword>
	<keyword>Taxol</keyword>
	<keyword>HER-2-negative</keyword>
	<keyword>First-Line Chemotherapy</keyword>
	<keyword>Second-Line Chemotherapy</keyword>
</DOC>